This article was originally published in The Tan Sheet
Executive SummaryFDA threatens enforcement action against the makers of unapproved topical prescription drugs with papain - an ingredient from the papaya plant that also is often used in dietary supplements - if they do not halt production by Nov. 24 or shipping by Jan. 21. The agency issued the warning Sept. 23 after receiving 37 serious adverse event reports about topical drugs with papain, including low blood pressure, rapid heart rate and allergic reactions, according to an agency official. FDA also ordered a stop to the production and shipping of unapproved ophthalmic balanced salt solution drug products used to irrigate the eye during surgery
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.